Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for FEMARA
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer
- Letrozole in Uterine Leiomyosarcoma
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
- Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
- Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles
- SMMART Adaptive Clinical Treatment (ACT) Trial
- Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
- Evaluation of Different Doses of Letrozole in Ectopic Pregnancy
- Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-II Breast Cancer
- Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon
- Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
- Efficacy of Letrozole Versus Clomiphene Citrate on Ovulation Induction in Patients With Polycystic Ovarian Syndrome
- Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
- Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance
- the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
- Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
- Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- Pharmacokinetics and Hepatic Safety of EGCG
- The Outcomes of ICSI Cycles With and Without Letrozole
- The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
- MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
- Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Follicular Synchronization in PCOS Patients Undergoing ICSI
- Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
- Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
- FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
- Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
- Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?
- Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
- Converting HR+ Breast Cancer Into an Individualized Vaccine
- Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
- Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
- To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast Cancer
- Endometrial Preparation in Frozen Embryo Transfer Cycles
- Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)
- Different Methods of Termination of Second Trimester Abortion
- Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
- Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
- Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
- Study of Letrozole in Recurrent Gliomas
- Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
- Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
- Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization
- Combined Letrozole and Clomid in Women With Infertility and PCOS
- Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
- A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
- Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility
- A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
- Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
- Administration of Single High Dose Letrozole for Ovulation Induction
- Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- The Letrozole Administration During Luteal Phase
- Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS
- Fertility Preservation in Breast Cancer Patients
- Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
- Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
- Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
- Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
- Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )
- Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
- Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
- Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer
- The Clinical Trial of Acupuncture Pre-treatment on PCOS
- A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix
- Pilot of Letrozole for Uterine Myomas
- Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion
- Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion
- Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
- Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)
- Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.
- Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Phase II Study of Everolimus Beyond Progression
- Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
- Comparison of Treatment Modalities in Poor Responders Undergoing IVF
- Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
- Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men
- GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
- Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
- TRial on the Endocrine Activity of Neoadjuvant Degarelix
- The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients
- Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
- A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
- Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Aromatase Inhibitor Host Factors Study
- Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
- Reproductive Hormonal Alterations in Obesity
- Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions
- Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions
- Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
- Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
- Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
- Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
- Dosage Optimization for Letrozole Treatment
- Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis
- RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
- Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
- Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
- Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
- Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
- Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
- Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
- Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
- Letrozole as a Treatment of Endometrial Cancer
- Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.
- Aromatase Inhibitors for Treatment of Uterine Leiomyomas
- Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome
- Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
- Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
- Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
- Antagonist/Letrozole in Poor Responders
- Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?
- Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
- Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
- Pregnancy in Polycystic Ovary Syndrome II
- Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
- Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
- Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
- Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
- Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
- Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
- GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
- Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
- Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
- Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
- Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
- Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer
- Letrozole in Patients With Ovarian Tumors
- PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
- Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
- Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
- Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
- Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
- Letrozole Treatment in Normal and GnRH Deficient Women
- Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
- Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
- Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Protocol for Women at Increased Risk of Developing Breast Cancer
- Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
- FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole
- Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
- Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
- Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
- Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Letrozole in Preventing Breast Cancer in Postmenopausal Women
- Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
- Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Letrozole After Tamoxifen in Treating Women With Breast Cancer
Clinical trials list
click for details